Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iodine I 131 derlotuximab biotin

Drug Profile

Iodine I 131 derlotuximab biotin

Alternative Names: 131-I chTNT 1/B; 131-I-chTNT-1/B mAb; Cotara; Iodine-131 radiolabelled TNT monoclonal antibody; Monoclonal antibody TNT-1; TNT-1; Tumour necrosis therapy-1

Latest Information Update: 09 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peregrine Pharmaceuticals
  • Developer Avid Bioservices; MediPharm Biotech
  • Class Antineoplastics; Iodine radioisotopes; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaplastic astrocytoma; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Lung cancer
  • Phase II Glioblastoma

Most Recent Events

  • 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
  • 12 Aug 2015 Phase-II development for Glioblastoma is ongoing in USA and India; advancement to phase III is dependent upon securing a partner
  • 06 Dec 2012 Peregrine plans a phase III trial for Glioblastoma (recurrent) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top